Industry
Drug Manufacturers - Specialty & Generic
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
Loading...
Open
0.87
Mkt cap
15M
Volume
38K
High
0.93
P/E Ratio
-1.46
52-wk high
1.61
Low
0.86
Div yield
N/A
52-wk low
0.43
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 3:46 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 2:51 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 8:09 pm
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 1:12 pm
Portfolio Pulse from Benzinga Insights
April 16, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
March 28, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
March 11, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Insights
March 08, 2024 | 9:31 pm
Portfolio Pulse from Benzinga Insights
March 07, 2024 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
March 07, 2024 | 12:12 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.